CARDIAC Valve Disease

Our multidisciplinary team is a national leader in cardiac valve disease. Our extensive minimally invasive and transcutaneous heart valve programs were built upon our decades-long reputation for excellence in surgical valve procedures. We offer patients the latest open surgical and percutaneous options for all valve conditions and specialize in the management of cardiac valves over a lifetime.

The University of Michigan has long been at the forefront of aortic valve surgery. Today, the Frankel CVC offers patients a variety of minimally invasive treatment options, including cutting-edge transcatheter valve repair and replacement techniques. We consistently earn national recognition as “High Performing” in aortic valve repair or replacement and transcatheter aortic valve replacement (TAVR) by U.S. News & World Report in its annual quality and safety rankings.

We are an internationally recognized leader in aortic valve repair for patients with aortic insufficiency or aortic root aneurysm. Our team developed a novel aortic annular enlargement technique for patients needing aortic valve replacement. Approximately half of our surgical aortic valve replacement cases benefit from annular enlargement, allowing us to use larger prosthetic valves to achieve improved patient outcomes.

The Frankel CVC offers the most comprehensive tricuspid valve treatment program in the state founded on excellent outcomes with a breadth of minimally invasive and conventional surgical options. Additionally, we are one of the few centers nationally to participate in a broad spectrum of percutaneous repair and replacement clinical trials. This includes valve replacement, edge to edge repair, and annuloplasty devices for the treatment of tricuspid valve disease, enabling us to provide appropriate patients access to next-generation technologies.

HIGH PERFORMANCE RECOGNITION FOR TAVR EXPERT

HIGH PERFORMANCE RECOGNITION FOR AORTIC VALVE SURGERY

As one of the largest and longest-standing mitral valve centers in the country, and the largest in Michigan, the Frankel CVC is nationally recognized for expertise in mitral valve repair and treatment. U-M Health was among the first five medical centers in the U.S. to receive a Mitral Valve Repair Reference Center Award based on our high volume of mitral valve procedures, superior clinical and patient outcomes, and the highest mitral repair rates. Surgical procedures are commonly performed via minimally invasive techniques without sternotomy. With numerous approved and clinical trial percutaneous repair and replacement devices available to treat all aspects of mitral valve disease, we offer patients an extensive range of treatment options

For information about our many active clinical trials, visit UMHealthResearch.org.

Through our robust clinical trials program, patients who are not candidates for commercially approved transcatheter and/or surgical therapies have access to a wide variety of alternative treatment options not available at other sites in Michigan. The Frankel CVC is currently participating in 18 valve trials.

U-M Health is pioneering the use of ShortCut™ technology to split bioprosthetic aortic valve leaflets for patients who are at risk for TAVR-induced coronary artery obstruction following a valve-in-valve procedure. We are among the first five programs in the U.S. to use this technology to treat patients with failing aortic valves and difficult aortic anatomies.

2,388

RECOGNIZED

For Best Practices In Mitral Valve Repair

U-M TAVR TICKER

2,388 AORTIC VALVES REPLACED AND COUNTING

CURRENTLY PARTICIPATING IN 18 VALVE

Clinical Trials

TAVR: 5 MITRAL: 8 TRICUSPID: 5